Optas, LLC Vertex Pharmaceuticals Inc Transaction History

Optas, LLC

  • $361 Million
  • Q1 2024

A detailed history of Optas, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Optas, LLC holds 754 shares of VRTX stock, worth $363,345. This represents 0.09% of its overall portfolio holdings.

Number of Shares
754
Previous 745 1.21%
Holding current value
$363,345
Previous $303,000 3.96%
% of portfolio
0.09%
Previous 0.09%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024
BUY
$407.69 - $446.08 $3,669 - $4,014
9 Added 1.21%
754 $315,000
Q4 2023

Jan 25, 2024
BUY
$343.0 - $410.68 $3,430 - $4,106
10 Added 1.36%
745 $303,000
Q3 2023

Oct 31, 2023
BUY
$338.18 - $362.46 $6,425 - $6,886
19 Added 2.65%
735 $255,000
Q2 2023

Jul 20, 2023
BUY
$314.42 - $351.91 $2,829 - $3,167
9 Added 1.27%
716 $251,000
Q1 2023

Apr 17, 2023
BUY
$283.23 - $323.1 $200,243 - $228,431
707 New
707 $222,000
Q4 2020

Jan 27, 2021
SELL
$207.01 - $276.09 $279,670 - $372,997
-1,351 Closed
0 $0
Q3 2020

Oct 23, 2020
BUY
$255.65 - $303.1 $119,899 - $142,153
469 Added 53.17%
1,351 $367,000
Q2 2020

Jul 31, 2020
SELL
$225.48 - $295.8 $30,439 - $39,933
-135 Reduced 13.27%
882 $256,000
Q1 2020

Apr 14, 2020
BUY
$199.77 - $247.81 $1,797 - $2,230
9 Added 0.89%
1,017 $241,000
Q4 2019

Feb 14, 2020
BUY
$166.71 - $223.91 $168,043 - $225,701
1,008 New
1,008 $220,000

Others Institutions Holding VRTX

# of Institutions
1,625
Shares Held
222M
Call Options Held
1.35M
Put Options Held
1.49M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $124B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Optas, LLC Portfolio

Follow Optas, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Optas, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Optas, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email